To include your compound in the COVID-19 Resource Center, submit it here.

BG-12: Additional Phase III data

Additional data from the double-blind, international Phase III DEFINE trial in >1,200 patients showed that twice-daily 240 mg oral BG-12 significantly reduced the proportion of patients who relapsed at 2 years, the primary endpoint,

Read the full 340 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE